GenSight Biologics on Track to Submit LUMEVOQ® for European Approval in September 2020 Following Pre-Submission Meeting With EMA

Print Friendly, PDF & Email

LHON INCLUDED IN THIS ARTICLE:  GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announces the completion of the pre-submission meeting with the European Medicines Agency (EMA) for the Company’s lead product LUMEVOQ […]